BIIB
NASDAQBiogen Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$187.93-1.33 (-0.71%)
01:30 PM07:45 PM
News · 26 weeks92+44%
2025-10-262026-04-19
Mix5990d
- Other22(37%)
- Insider22(37%)
- SEC Filings8(14%)
- Analyst5(8%)
- Earnings1(2%)
- Leadership1(2%)
Latest news
25 items- FDAFDA Approval for ZURZUVAE issued to BIOGEN INCSubmission status for BIOGEN INC's drug ZURZUVAE (SUPPL-3) with active ingredient ZURANOLONE has changed to 'Approval' on 04/20/2026. Application Category: NDA, Application Number: 217369, Application Classification: Labeling
- ANALYSTBiogen upgraded by UBS with a new price targetUBS upgraded Biogen from Neutral to Buy and set a new price target of $225.00
- ANALYSTBiogen upgraded by Wells Fargo with a new price targetWells Fargo upgraded Biogen from Equal Weight to Overweight and set a new price target of $250.00
- PRTJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China RegionWith this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global marketAgreement builds on TJ Biopharma's development success of felzartamab in China and productive clinical collaboration in Biogen-led Phase 3 trials for IgAN and PMN since April 2025CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and TJ Biopharma ("TJ Bio") today announced that the
- PRBiogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China RegionWith this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global marketAgreement builds on TJ Biopharma's development success of felzartamab in China and productive clinical collaboration in Biogen-led Phase 3 trials for IgAN and PMN since April 2025 CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and TJ Biopharma ("TJ Bio") today announced
- ANALYSTBiogen upgraded by Piper Sandler with a new price targetPiper Sandler upgraded Biogen from Neutral to Overweight and set a new price target of $214.00
- PRStoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:00 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therape
- PRStoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of DirectorsStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p
- SECBiogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - BIOGEN INC. (0000875045) (Filer)
- INSIDERSEC Form 4 filed by Godbout Sean4 - BIOGEN INC. (0000875045) (Issuer)
- SECSEC Form 8-K filed by Biogen Inc.8-K - BIOGEN INC. (0000875045) (Filer)
- PRBiogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyAcquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis' commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis' talent and expertise will accelerate Biogen's entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3Acquisition is expected to bolster Biogen's near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 n
- PRFDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyThe approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patientsHigh Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and Japan CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of cli
- PRBiogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease ActivityIn the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skinFollowing positive Phase 2 LILAC results, litifilimab is the only investigational program with consistent, positive efficacy results in multiple CLE studies; if approved litifilimab could be the first targeted therapy for this diseaseCLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced positive results from t
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.SCHEDULE 13G/A - BIOGEN INC. (0000875045) (Subject)
- PRResults from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI®), an anti‑amyloid‑β (Aβ) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment. The analysis was presented at the 20th International Conference on Alzheimer's an
- PRBiogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual MeetingLate-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designationCLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaki
- SECBiogen Inc. filed SEC Form 8-K: Leadership Update8-K - BIOGEN INC. (0000875045) (Filer)
- PRBiogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene TherapyNew Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapySalanersen is a novel antisense oligonucleotide and has the potential to deliver high efficacy in SMA with once-yearly dosingBiogen also debuted the design of the Phase 3 salanersen clinical trial program which is being initiated at sites around the world CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) presented additional results from the Phase 1b study of salanersen, an investigational novel antisense oligonucleotide (ASO) given once a year for spinal muscular
- PRBiogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe ConferencesLong-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high dose nusinersen and salanersen, at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 8-11, 2026) and 5th International Scientific Congress on SMA (S
- PRThe New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The publication includes results from two completed Phase 1/2a and ongoing open-label extension (OLE) studies that demonstra
- PRThe New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB), today announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journal of Medicine (NEJM). The publication includes results from two completed
- PRStoke Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therapeu
- ANALYSTBarclays initiated coverage on Biogen with a new price targetBarclays initiated coverage of Biogen with a rating of Equal Weight and set a new price target of $185.00
- INSIDERSEC Form 4 filed by President and CEO Viehbacher Christopher4 - BIOGEN INC. (0000875045) (Issuer)